Predictors and outcomes of healthcare-associated infections in COVID-19 patients

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved..

INTRODUCTION: Healthcare-associated infections (HAI) after viral illnesses are important sources of morbidity and mortality. This has not been extensively studied in hospitalized COVID-19 patients.

METHODS: This study included all COVID-19-positive adult patients (≥18 years) hospitalized between 01 March and 05 August 2020 at the current institution. The Centers for Disease Control and Prevention definition of HAI in the acute care setting was used. The outcomes that were studied were rates and types of infections and in-hospital mortality. Several multivariable logistic regression models were constructed to examine characteristics associated with development of HAI.

RESULTS: Fifty-nine (3.7%) of 1565 patients developed 140 separate HAIs from 73 different organisms: 23 were Gram-positive, 39 were Gram-negative and 11 were fungal. Patients who developed HAI did not have higher odds of death (OR 0.85, 95% CI 0.40-1.81, p =  0.69). HAIs were associated with the use of tocilizumab (OR 5.04, 95% CI 2.4-10.6, p <  0.001), steroids (OR 3.8, 95% CI 1.4-10, p =  0.007), hydroxychloroquine (OR 3.0, 95% CI 1.0-8.8, p =  0.05), and acute kidney injury requiring hemodialysis (OR 3.7, 95% CI 1.1-12.8, p =  0.04).

CONCLUSIONS: HAI were common in hospitalized Covid-19 patients. Tocilizumab and steroids were associated with increased risk of HAIs.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - Vol. 104 (2021), p. 287-292

Language:

English

Contributors:

Kumar, Gagan
Adams, Alex
Hererra, Martin
Rojas, Erine Raybon
Singh, Vartika
Sakhuja, Ankit
Meersman, Mark
Dalton, Drew
Kethireddy, Shravan
Nanchal, Rahul
Guddati, Achuta Kumar

Links:

Volltext

Keywords:

*Pandemics
*SARS-CoV-2
4QWG6N8QKH
Aged
Antibodies, Monoclonal, Humanized
COVID-19
Coinfection
Cross Infection
Female
Georgia
Hospital Mortality
Humans
Hydroxychloroquine
I031V2H011
Journal Article
Logistic Models
Male
Middle Aged
Multivariate Analysis
Retrospective Studies
Risk
Secondary infections
Steroids
Tocilizumab

Notes:

Date Completed 04.05.2021

Date Revised 12.06.2021

published: Print-Electronic

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1016/j.ijid.2020.11.135

PMID:

33207271

PPN (Catalogue-ID):

NLM318737043